{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:57:15Z","timestamp":1773925035943,"version":"3.50.1"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1038\/ncponc0693","type":"journal-article","created":{"date-parts":[[2006,12,21]],"date-time":"2006-12-21T10:48:08Z","timestamp":1166698088000},"page":"18-29","source":"Crossref","is-referenced-by-count":50,"title":["Quality of life for patients with epithelial ovarian cancer"],"prefix":"10.1038","volume":"4","author":[{"given":"Charlotte C","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro T","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane C","family":"Bodurka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncponc0693_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74\u2013108","journal-title":"CA Cancer J Clin"},{"key":"BFncponc0693_CR2","first-page":"895","volume-title":"Principles and Practice of Gynecologic Oncology","author":"R Ozols","year":"2005","unstructured":"Ozols R et al. (2005) Epithelial ovarian cancer. In Principles and Practice of Gynecologic Oncology, 895\u2013987 (Eds Hoskins W et al.) Philadelphia: Lippincott Williams & Wilkins"},{"issue":"Suppl","key":"BFncponc0693_CR3","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1006\/gyno.2002.6674","volume":"88","author":"J Boyd","year":"2003","unstructured":"Boyd J (2003) Hereditary ovarian cancer: what we know. Gynecol Oncol 88 (Suppl): S8\u2013S10","journal-title":"Gynecol Oncol"},{"key":"BFncponc0693_CR4","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z","volume":"89","author":"BA Goff","year":"2000","unstructured":"Goff BA et al. (2000) Ovarian carcinoma diagnosis. Cancer 89: 2068\u20132075","journal-title":"Cancer"},{"key":"BFncponc0693_CR5","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1001\/jama.291.22.2705","volume":"291","author":"BA Goff","year":"2004","unstructured":"Goff BA et al. (2004) Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291: 2705\u20132712","journal-title":"JAMA"},{"key":"BFncponc0693_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00006250-200108000-00006","volume":"98","author":"SH Olson","year":"2001","unstructured":"Olson SH et al. (2001) Symptoms of ovarian cancer. Obstet Gynecol 98: 212\u2013217","journal-title":"Obstet Gynecol"},{"key":"BFncponc0693_CR7","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1200\/JCO.2005.05.097","volume":"23","author":"D Stirling","year":"2005","unstructured":"Stirling D et al. (2005) Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics system. J Clin Oncol 23: 5588\u20135596","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR8","doi-asserted-by":"publisher","first-page":"7919","DOI":"10.1200\/JCO.2005.01.6642","volume":"23","author":"U Menon","year":"2005","unstructured":"Menon U et al. (2005) Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23: 7919\u20137926","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR9","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1200\/JCO.1997.15.11.3408","volume":"15","author":"KA Munoz","year":"1997","unstructured":"Munoz KA et al. (1997) Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 15: 3408\u20133415","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34\u201343","journal-title":"N Engl J Med"},{"key":"BFncponc0693_CR11","unstructured":"FIGO Staging Committee (1986) International Federation of Gynecology and Obstetrics Staging Announcement. Gynecol Oncol 25: 383\u2013385"},{"key":"BFncponc0693_CR12","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248\u20131259","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR13","doi-asserted-by":"crossref","unstructured":"Bookman M (2006) GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract #5002]. J Clin Oncol","DOI":"10.1200\/jco.2006.24.18_suppl.5002"},{"key":"BFncponc0693_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/jnci\/djh194","volume":"96","author":"KL Taylor","year":"2004","unstructured":"Taylor KL et al. (2004) Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J Natl Cancer Inst 96: 1083\u20131094","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0693_CR15","first-page":"47","volume":"9","author":"DF Cella","year":"1995","unstructured":"Cella DF and Bonomi AE (1995) Measuring quality of life: 1995 update. Oncology (Williston Park) 9: 47\u201360","journal-title":"Oncology (Williston Park)"},{"key":"BFncponc0693_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ijnurstu.2004.07.008","volume":"42","author":"K Ahlberg","year":"2005","unstructured":"Ahlberg K et al. (2005) The experience of fatigue, other symptoms and global quality of life during radiotherapy for uterine cancer. Int J Nurs Stud 42: 377\u2013386","journal-title":"Int J Nurs Stud"},{"key":"BFncponc0693_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1034\/j.1600-0412.2002.810512.x","volume":"81","author":"K Bergmark","year":"2002","unstructured":"Bergmark K et al. (2002) Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta Obstet Gynecol Scand 81: 443\u2013450","journal-title":"Acta Obstet Gynecol Scand"},{"key":"BFncponc0693_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1006\/gyno.2002.6849","volume":"88","author":"YM Chan","year":"2003","unstructured":"Chan YM et al. (2003) Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 88: 9\u201316","journal-title":"Gynecol Oncol"},{"key":"BFncponc0693_CR19","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1200\/JCO.2005.08.041","volume":"23","author":"K Ell","year":"2005","unstructured":"Ell K et al. (2005) Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J Clin Oncol 23: 3052\u20133060","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2005.03.3654","volume":"24","author":"LJ Fallowfield","year":"2006","unstructured":"Fallowfield LJ et al. (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24: 910\u2013917","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR21","doi-asserted-by":"publisher","first-page":"7428","DOI":"10.1200\/JCO.2004.00.3996","volume":"23","author":"M Frumovitz","year":"2005","unstructured":"Frumovitz M et al. (2005) Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 23: 7428\u20137436","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.2005.04.8678","volume":"24","author":"RS Herbst","year":"2006","unstructured":"Herbst RS et al.; American Society of Clinical Oncology (2006) Clinical cancer advances 2005: major research advances in cancer treatment, prevention, and screening\u2014a report from the American Society of Clinical Oncology. J Clin Oncol 24: 190\u2013205","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/ijgc-00009577-200409000-00021","volume":"14","author":"M Janda","year":"2004","unstructured":"Janda M et al. (2004) Vulvar cancer patients' quality of life: a qualitative assessment. Int J Gynecol Cancer 14: 875\u2013881","journal-title":"Int J Gynecol Cancer"},{"key":"BFncponc0693_CR24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/01.OGX.0000093269.99295.8E","volume":"58","author":"T Le","year":"2003","unstructured":"Le T et al. (2003) Quality-of-life issues in patients with ovarian cancer and their caregivers: a review. Obstet Gynecol Surv 58: 749\u2013758","journal-title":"Obstet Gynecol Surv"},{"key":"BFncponc0693_CR25","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1072-7515(01)01090-0","volume":"193","author":"N Gillette-Cloven","year":"2001","unstructured":"Gillette-Cloven N et al. (2001) Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. J Am Coll Surg 193: 626\u2013632","journal-title":"J Am Coll Surg"},{"key":"BFncponc0693_CR26","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/0277-9536(92)90053-S","volume":"35","author":"SA Payne","year":"1992","unstructured":"Payne SA (1992) A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 35: 1505\u20131509","journal-title":"Soc Sci Med"},{"key":"BFncponc0693_CR27","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2229::AID-CNCR27>3.0.CO;2-#","volume":"78","author":"CR Ratliff","year":"1996","unstructured":"Ratliff CR et al. (1996) Sexual adjustment of patients undergoing gracilis myocutaneous flap vaginal reconstruction in conjunction with pelvic exenteration. Cancer 78: 2229\u20132235","journal-title":"Cancer"},{"key":"BFncponc0693_CR28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ygyno.2004.03.008","volume":"93","author":"EJ Roos","year":"2004","unstructured":"Roos EJ et al. (2004) Quality of life after pelvic exenteration. Gynecol Oncol 93: 610\u2013614","journal-title":"Gynecol Oncol"},{"key":"BFncponc0693_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S1470-2045(05)70432-0","volume":"6","author":"MJ Taphoorn","year":"2005","unstructured":"Taphoorn MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumour Group; EORTC Radiotherapy Group; National Cancer Institute of Canada Clinical Trials Group (2005) Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6: 937\u2013944","journal-title":"Lancet Oncol"},{"key":"BFncponc0693_CR30","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ajog.2004.12.081","volume":"192","author":"L Zhu","year":"2005","unstructured":"Zhu L et al. (2005) Quality-of-life analysis in the management of endometrial cancer. Am J Obstet Gynecol 192: 1388\u20131390","journal-title":"Am J Obstet Gynecol"},{"key":"BFncponc0693_CR31","first-page":"3321","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN et al. (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of peglyated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3321\u20133322","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR32","first-page":"a603","volume":"19","author":"M Coenen","year":"2000","unstructured":"Coenen M et al. (2000) Gemcitabine in platinum-paclitaxel resistant ovarian carcinoma [abstract]. Proc Am Soc Clin Oncol 19: a603","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BFncponc0693_CR33","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1023\/A:1008469212268","volume":"9","author":"M Freidlander","year":"1998","unstructured":"Freidlander M et al. (1998) A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 9: 1343\u20131345","journal-title":"Ann Oncol"},{"key":"BFncponc0693_CR34","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","volume":"86","author":"B Lund","year":"1994","unstructured":"Lund B et al. (1994) Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530\u20131533","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0693_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","volume":"16","author":"PG Rose","year":"1998","unstructured":"Rose PG et al. (1998) Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16: 405\u2013410","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0693_CR37","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF et al. (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11: 570\u2013579","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0959-8049(00)00369-5","volume":"37","author":"A Cull","year":"2001","unstructured":"Cull A et al. (2001) Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 37: 47\u201353","journal-title":"Eur J Cancer"},{"key":"BFncponc0693_CR39","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","volume":"39","author":"E Greimel","year":"2003","unstructured":"Greimel E et al. (2003) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 39: 1402\u20131408","journal-title":"Eur J Cancer"},{"key":"BFncponc0693_CR40","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1200\/JCO.2001.19.6.1809","volume":"19","author":"K Basen-Engquist","year":"2001","unstructured":"Basen-Engquist K et al. (2001) Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 19: 1809\u20131817","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1200\/JCO.2001.19.1.220","volume":"19","author":"AM Stiggelbout","year":"2001","unstructured":"Stiggelbout AM and de Haes JC (2001) Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol 19: 220\u2013230","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR42","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ygyno.2004.01.017","volume":"93","author":"EA Calhoun","year":"2004","unstructured":"Calhoun EA et al. (2004) A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol 93: 164\u2013169","journal-title":"Gynecol Oncol"},{"key":"BFncponc0693_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1006\/gyno.2002.6807","volume":"87","author":"CC Sun","year":"2002","unstructured":"Sun CC et al. (2002) Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol 87: 118\u2013128","journal-title":"Gynecol Oncol"},{"key":"BFncponc0693_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC et al. (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13: 219\u2013227","journal-title":"Support Care Cancer"},{"key":"BFncponc0693_CR45","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/01.GME.0000139926.02689.A1","volume":"11","author":"A Graziottin","year":"2004","unstructured":"Graziottin A and Basson R (2004) Sexual dysfunction in women with premature menopause. Menopause 11: 766\u2013777","journal-title":"Menopause"},{"key":"BFncponc0693_CR46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321\u2013333","journal-title":"JAMA"},{"key":"BFncponc0693_CR47","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1200\/JCO.1998.16.7.2377","volume":"16","author":"CL Loprinzi","year":"1998","unstructured":"Loprinzi CL et al. (1998) Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 16: 2377\u20132381","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1188\/02.ONF.33-40","volume":"29","author":"D Barton","year":"2002","unstructured":"Barton D et al. (2002) Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 29: 33\u201340","journal-title":"Oncol Nurs Forum"},{"key":"BFncponc0693_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1075-122X.2006.00218.x","volume":"12","author":"GG Kimmick","year":"2006","unstructured":"Kimmick GG et al. (2006) Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 12: 114\u2013122","journal-title":"Breast J"},{"key":"BFncponc0693_CR50","unstructured":"Bodurka D et al. (2005) Ovarian cancer: quality of life issues. Boca Raton: National Ovarian Cancer Coalition"},{"key":"BFncponc0693_CR51","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/pon.567","volume":"11","author":"LB Wenzel","year":"2002","unstructured":"Wenzel LB et al. (2002) Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology 11: 142\u2013153","journal-title":"Psychooncology"},{"key":"BFncponc0693_CR52","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.2004.08.150","volume":"22","author":"CL Carmack Taylor","year":"2004","unstructured":"Carmack Taylor CL et al. (2004) Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol 22: 881\u2013889","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR53","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ygyno.2004.05.034","volume":"94","author":"RT Penson","year":"2004","unstructured":"Penson RT et al. (2004) Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol 94: 427\u2013435","journal-title":"Gynecol Oncol"},{"key":"BFncponc0693_CR54","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/bmj.323.7317.836","volume":"323","author":"ML Stead","year":"2001","unstructured":"Stead ML et al. (2001) Communication about sexual problems and sexual concerns in ovarian cancer: qualitative study. BMJ 323: 836\u2013837","journal-title":"BMJ"},{"key":"BFncponc0693_CR55","unstructured":"Bodurka DCSC et al. (2005) Helping cancer patients with quality of life treatment decisions (audio CD). ACOG update 31: October 2005"},{"key":"BFncponc0693_CR56","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1006\/gyno.2001.6437","volume":"83","author":"DE Stewart","year":"2001","unstructured":"Stewart DE et al. (2001) \u201dWhat doesn't kill you makes you stronger\u201d: an ovarian cancer survivor survey. Gynecol Oncol 83: 537\u2013542","journal-title":"Gynecol Oncol"},{"key":"BFncponc0693_CR57","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1053\/sonu.2002.34084","volume":"18","author":"M Tabano","year":"2002","unstructured":"Tabano M et al. (2002) Symptoms affecting quality of life in women with gynecologic cancer. Semin Oncol Nurs 18: 223\u2013230","journal-title":"Semin Oncol Nurs"},{"key":"BFncponc0693_CR58","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/jncimonographs\/lgi017","volume":"34","author":"L Wenzel","year":"2005","unstructured":"Wenzel L et al. (2005) Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr (34): 94\u201398","journal-title":"J Natl Cancer Inst Monogr"},{"key":"BFncponc0693_CR59","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/jncimonographs\/lgi012","volume":"(34)","author":"LC Friedman","year":"2005","unstructured":"Friedman LC and Kramer RM (2005) Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr (34): 83\u201386","journal-title":"J Natl Cancer Inst Monogr"},{"key":"BFncponc0693_CR60","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0090-8258(03)00072-6","volume":"89","author":"M Robson","year":"2003","unstructured":"Robson M et al. (2003) Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 89: 281\u2013287","journal-title":"Gynecol Oncol"},{"key":"BFncponc0693_CR61","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","volume":"103","author":"DS Chi","year":"2006","unstructured":"Chi DS et al. (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103: 559\u2013564","journal-title":"Gynecol Oncol"},{"key":"BFncponc0693_CR62","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1006\/gyno.2001.6313","volume":"82","author":"SM Eisenkop","year":"2001","unstructured":"Eisenkop SM and Spirtos NM (2001) Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with \u201cbiological aggressiveness\u201d and survival? Gynecol Oncol 82: 435\u2013441","journal-title":"Gynecol Oncol"},{"key":"BFncponc0693_CR63","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0090-8258(03)00073-8","volume":"89","author":"B Pothuri","year":"2003","unstructured":"Pothuri B et al. (2003) Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol 89: 306\u2013313","journal-title":"Gynecol Oncol"},{"key":"BFncponc0693_CR64","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ygyno.2004.09.058","volume":"96","author":"B Pothuri","year":"2005","unstructured":"Pothuri B et al. (2005) Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol 96: 330\u2013334","journal-title":"Gynecol Oncol"},{"key":"BFncponc0693_CR65","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00520-002-0416-6","volume":"11","author":"Y Kim","year":"2003","unstructured":"Kim Y and Morrow GR (2003) Changes in family relationships affect the development of chemotherapy-related nausea symptoms. Support Care Cancer 11: 171\u2013177","journal-title":"Support Care Cancer"},{"key":"BFncponc0693_CR66","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/BF00434947","volume":"1","author":"CM Lindley","year":"1992","unstructured":"Lindley CM et al. (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1: 331\u2013340","journal-title":"Qual Life Res"},{"key":"BFncponc0693_CR67","first-page":"296","volume":"149","author":"BJ O'Brien","year":"1993","unstructured":"O'Brien BJ et al. (1993) Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ 149: 296\u2013302","journal-title":"CMAJ"},{"key":"BFncponc0693_CR68","first-page":"113","volume":"3","author":"KM Doherty","year":"1993","unstructured":"Doherty KM (1993) Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 3: 113\u2013119","journal-title":"Clin J Oncol Nurs"},{"key":"BFncponc0693_CR69","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3109\/07357900009038248","volume":"18","author":"PJ Hesketh","year":"2000","unstructured":"Hesketh PJ (2000) Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 18: 163\u2013173","journal-title":"Cancer Invest"},{"key":"BFncponc0693_CR70","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/ncponc0132","volume":"2","author":"TH Oo","year":"2005","unstructured":"Oo TH and Hesketh PJ (2005) Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol 2: 196\u2013201","journal-title":"Nat Clin Pract Oncol"},{"key":"BFncponc0693_CR71","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1200\/JCO.2006.06.9591","volume":"24","author":"MG Kris","year":"2006","unstructured":"Kris MG et al. (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24: 2932\u20132947","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR72","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0749-2081(03)00059-7","volume":"19","author":"SJ Edwards","year":"2003","unstructured":"Edwards SJ (2003) Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer. Semin Oncol Nurs 19: 19\u201339","journal-title":"Semin Oncol Nurs"},{"key":"BFncponc0693_CR73","first-page":"444","volume-title":"Cancer Nursing Principles and Practice","author":"D Camp-Sorrell","year":"2000","unstructured":"Camp-Sorrell D (2000) Chemotherapy: toxicity management. In Cancer Nursing Principles and Practice, 444\u2013486 (Eds Yarbro C et al.) Sudbury: Jones and Bartlett"},{"key":"BFncponc0693_CR74","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1188\/02.CJON.163-166","volume":"6","author":"CW Sweeney","year":"2002","unstructured":"Sweeney CW (2002) Understanding peripheral neuropathy in patients with cancer: background and patient assessment. Clin J Oncol Nurs 6: 163\u2013166","journal-title":"Clin J Oncol Nurs"},{"key":"BFncponc0693_CR75","first-page":"619","volume":"12","author":"AJ Ocean","year":"2004","unstructured":"Ocean AJ and Bahdat LT (2004) Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12: 619\u2013625","journal-title":"Support Care Cancer"},{"key":"BFncponc0693_CR76","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1081\/CNV-120018236","volume":"21","author":"C Visovsky","year":"2003","unstructured":"Visovsky C (2003) Chemotherapy-induced peripheral neuropathy. Cancer Invest 21: 439\u2013451","journal-title":"Cancer Invest"},{"key":"BFncponc0693_CR77","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/ijgc-00009577-200301000-00002","volume":"13","author":"W Boling","year":"2003","unstructured":"Boling W et al. (2003) Health-related quality of life in gynecological oncology: instruments and psychometric properties. Int J Gynecol Cancer 13: 5\u201314","journal-title":"Int J Gynecol Cancer"},{"key":"BFncponc0693_CR78","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/cncr.10630","volume":"95","author":"N Carelle","year":"2002","unstructured":"Carelle N et al. (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95: 155\u2013163","journal-title":"Cancer"},{"key":"BFncponc0693_CR79","unstructured":"National Comprehensive Cancer Network (2006) Cancer- and treatment-related anemia. Cancer Practice Guidelines in Oncology, Version 1 [ http:\/\/www.nccn.org ] (accessed 28 November 2006)"},{"key":"BFncponc0693_CR80","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0093-7754(01)90206-4","volume":"28","author":"H Ludwig","year":"2001","unstructured":"Ludwig H and Strasser K (2001) Symptomatology of anemia. Semin Oncol 28: 7\u201314","journal-title":"Semin Oncol"},{"key":"BFncponc0693_CR81","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","volume":"91","author":"JE Groopman","year":"1999","unstructured":"Groopman JE and Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616\u20131634","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0693_CR82","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/cncr.11253","volume":"97","author":"B Holzner","year":"2003","unstructured":"Holzner B et al. (2003) Fatigue in ovarian carcinoma patients: a neglected issue? Cancer 97: 1564\u20131572","journal-title":"Cancer"},{"key":"BFncponc0693_CR83","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1023\/A:1021119405814","volume":"1","author":"L Elit","year":"2001","unstructured":"Elit L et al. (2001) Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer 1: 149\u2013156","journal-title":"Fam Cancer"},{"key":"BFncponc0693_CR84","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/pon.512","volume":"10","author":"A Fry","year":"2001","unstructured":"Fry A et al. (2001) Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology 10: 231\u2013241","journal-title":"Psychooncology"},{"key":"BFncponc0693_CR85","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1200\/JCO.2004.07.028","volume":"22","author":"TR Norton","year":"2004","unstructured":"Norton TR et al. (2004) Prevalence and predictors of psychological distress among women with ovarian cancer. J Clin Oncol 22: 919\u2013926","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR86","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/cncr.11291","volume":"98","author":"B Ferrell","year":"2003","unstructured":"Ferrell B et al. (2003) Psychological well being and quality of life in ovarian cancer survivors. Cancer 98: 1061\u20131071","journal-title":"Cancer"},{"key":"BFncponc0693_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00002820-200302000-00001","volume":"26","author":"D Howell","year":"2003","unstructured":"Howell D et al. (2003) Impact of ovarian cancer perceived by women. Cancer Nurs 26: 1\u20139","journal-title":"Cancer Nurs"},{"key":"BFncponc0693_CR88","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3109\/07357909909032875","volume":"17","author":"AB Hamilton","year":"1999","unstructured":"Hamilton AB (1999) Psychological aspects of ovarian cancer. Cancer Invest 17: 335\u2013341","journal-title":"Cancer Invest"},{"key":"BFncponc0693_CR89","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351: 2519\u20132529","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"BFncponc0693_CR90","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1136\/ijgc-00009577-200505001-00002","volume":"15","author":"RF Ozols","year":"2005","unstructured":"Ozols RF (2005) Treatment goals in ovarian cancer. Int J Gynecol Cancer 15 (Suppl 1): S3\u2013S11","journal-title":"Int J Gynecol Cancer"},{"key":"BFncponc0693_CR91","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1200\/JCO.1995.13.5.1062","volume":"13","author":"C Daugherty","year":"1995","unstructured":"Daugherty C et al. (1995) Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 13: 1062\u20131072","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR92","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1200\/JCO.2001.19.5.1266","volume":"19","author":"C Doyle","year":"2001","unstructured":"Doyle C et al. (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19: 1266\u20131274","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR93","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMsa021182","volume":"347","author":"S Horng","year":"2002","unstructured":"Horng S et al. (2002) Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med 347: 2134\u20132140","journal-title":"N Engl J Med"},{"key":"BFncponc0693_CR94","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ygyno.2005.01.031","volume":"97","author":"VE von Gruenigen","year":"2005","unstructured":"von Gruenigen VE and Daly BJ (2005) Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol 97: 638\u2013644","journal-title":"Gynecol Oncol"},{"key":"BFncponc0693_CR95","first-page":"1021","volume":"13","author":"WF Baile","year":"1999","unstructured":"Baile WF et al. (1999) Discussing disease progression and end-of-life decisions. Oncology (Williston Park) 13: 1021\u20131031; discussion 1031\u20131036, 1038","journal-title":"Oncology (Williston Park)"},{"key":"BFncponc0693_CR96","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/B978-0-443-07142-3.50058-0","volume-title":"Gynecologic Cancer: Controversies in Management","author":"C Chu","year":"2004","unstructured":"Chu C and Rubin SC (2004) Management of intestinal obstruction in the terminal patient and management of ascites. In Gynecologic Cancer: Controversies in Management, 727\u2013741 (Eds Gershenson DM et al.) Philadelphia: Elsevier Ltd"},{"key":"BFncponc0693_CR97","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1200\/JCO.2004.02.056","volume":"22","author":"MK Whitworth","year":"2004","unstructured":"Whitworth MK et al. (2004) Doctor, does this mean I'm going to starve to death? J Clin Oncol 22: 199\u2013201","journal-title":"J Clin Oncol"},{"key":"BFncponc0693_CR98","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/B978-0-443-07142-3.50059-2","volume-title":"Gynecologic Cancer: Controversies in Management","author":"R Buckman","year":"2004","unstructured":"Buckman R and Baile W (2004) Death and dying. In Gynecologic Cancer: Controversies in Management, 743\u2013752 (Eds Gershenson DM et al.) Philadelphia: Elsevier Ltd"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc0693.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0693","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncponc0693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0693.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:44:53Z","timestamp":1684442693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["BFncponc0693"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0693","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}